|
1
|
Gansler T, Ganz PA, Grant M, Greene FL,
Johnstone P, Mahoney M, Newman LA, Oh WK, Thomas CR Jr, Thun MJ, et
al: Sixty years of CA: A cancer journal for clinicians. CA Cancer J
Clin. 60:345–350. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Coward JI, Middleton K and Murphy F: New
perspectives on targeted therapy in ovarian cancer. Int J Womens
Health. 7:189–203. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cannistra SA: Cancer of the ovary. N Engl
J Med. 351:2519–2529. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kreienbring K, Franz A, Richter R, Dragun
D, Heidecke H, Müller D, Mentze M, Dechend R, Sehouli J and Braicu
EI: The role of PAR1 autoantibodies in patients with primary
epithelial ovarian cancer. Anticancer Res. 38:3619–3625. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
du Bois A, Reuss A, Pujade-Lauraine E,
Harter P, Ray-Coquard I and Pfisterer J: Role of surgical outcome
as prognostic factor in advanced epithelial ovarian cancer: A
combined exploratory analysis of 3 prospectively randomized phase 3
multicenter trials: By the Arbeitsgemeinschaft Gynaekologische
Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe
d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire
(GINECO). Cancer. 115:1234–1244. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ozols RF, Bundy BN, Greer BE, Fowler JM,
Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM
and Baergen R; Gynecologic Oncology Group, : Phase III trial of
carboplatin and paclitaxel compared with cisplatin and paclitaxel
in patients with optimally resected stage III ovarian cancer: A
Gynecologic Oncology Group study. J Clin Oncol. 21:3194–3200. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Derlatka P, Sienko J, Grabowska-Derlatka
L, Palczewski P, Danska-Bidzinska A, Bidzinski M and Czajkowski K:
Results of optimal debulking surgery with bowel resection in
patients with advanced ovarian cancer. World J Surg Oncol.
14:582016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bristow RE, Tomacruz RS, Armstrong DK,
Trimble EL and Montz FJ: Survival effect of maximal cytoreductive
surgery for advanced ovarian carcinoma during the platinum era: A
meta-analysis. J Clin Oncol. 20:1248–1259. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dressman HK, Berchuck A, Chan G, Zhai J,
Bild A, Sayer R, Cragun J, Clarke J, Whitaker RS, Li L, et al: An
integrated genomic-based approach to individualized treatment of
patients with advanced-stage ovarian cancer. J Clin Oncol.
25:517–525. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cramer DW, Harlow BL, Willett WC, Welch
WR, Bell DA, Scully RE, Ng WG and Knapp RC: Galactose consumption
and metabolism in relation to the risk of ovarian cancer. Lancet.
2:66–71. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Webb PM, Bain CJ, Purdie DM, Harvey PW and
Green A: Milk consumption, galactose metabolism and ovarian cancer
(Australia). Cancer Causes Control. 9:637–644. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nieman KM, Kenny HA, Penicka CV, Ladanyi
A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB,
Hotamisligil GS, et al: Adipocytes promote ovarian cancer
metastasis and provide energy for rapid tumor growth. Nat Med.
17:1498–1503. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Warburg O: On the origin of cancer cells.
Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gambhir SS: Molecular imaging of cancer
with positron emission tomography. Nat Rev Cancer. 2:683–693. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lunt SY and Vander Heiden MG: Aerobic
glycolysis: Meeting the metabolic requirements of cell
proliferation. Annu Rev Cell Dev Biol. 27:441–464. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schornack PA and Gillies RJ: Contributions
of cell metabolism and H+ diffusion to the acidic pH of tumors.
Neoplasia. 5:135–145. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Smallbone K, Gavaghan DJ, Gatenby RA and
Maini PK: The role of acidity in solid tumour growth and invasion.
J Theor Biol. 235:476–484. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fumarola C, Petronini PG and Alfieri R:
Impairing energy metabolism in solid tumors through agents
targeting oncogenic signaling pathways. Biochem Pharmacol.
151:114–125. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sonveaux P, Végran F, Schroeder T, Wergin
MC, Verrax J, Rabbani ZN, De Saedeleer CJ, Kennedy KM, Diepart C,
Jordan BF, et al: Targeting lactate-fueled respiration selectively
kills hypoxic tumor cells in mice. J Clin Invest. 118:3930–3942.
2008.PubMed/NCBI
|
|
20
|
Whitaker-Menezes D, Martinez-Outschoorn
UE, Flomenberg N, Birbe RC, Witkiewicz AK, Howell A, Pavlides S,
Tsirigos A, Ertel A, Pestell RG, et al: Hyperactivation of
oxidative mitochondrial metabolism in epithelial cancer cells in
situ: Visualizing the therapeutic effects of metformin in tumor
tissue. Cell Cycle. 10:4047–4064. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Faubert B, Li KY, Cai L, Hensley CT, Kim
J, Zacharias LG, Yang C, Do QN, Doucette S, Burguete D, et al:
Lactate metabolism in human lung tumors. Cell. 171:358–371.e9.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bonuccelli G, Tsirigos A, Whitaker-Menezes
D, Pavlides S, Pestell RG, Chiavarina B, Frank PG, Flomenberg N,
Howell A, Martinez-Outschoorn UE, et al: Ketones and lactate ‘fuel’
tumor growth and metastasis: Evidence that epithelial cancer cells
use oxidative mitochondrial metabolism. Cell Cycle. 9:3506–3514.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Le A, Lane AN, Hamaker M, Bose S, Gouw A,
Barbi J, Tsukamoto T, Rojas CJ, Slusher BS, Zhang H, et al:
Glucose-independent glutamine metabolism via TCA cycling for
proliferation and survival in B cells. Cell Metab. 15:110–121.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Prudkov PN: Mental effort and fatigue as
consequences of monotony. Behav Brain Sci. 36:702–703; discussion
707–726. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu F, Zhao Z, Chai RC, Liu YQ, Li GZ,
Jiang HY and Jiang T: Prognostic power of a lipid metabolism gene
panel for diffuse gliomas. J Cell Mol Med. 23:7741–7748. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhou Z, Huang R, Chai R, Zhou X, Hu Z,
Wang W, Chen B, Deng L, Liu Y and Wu F: Identification of an energy
metabolism-related signature associated with clinical prognosis in
diffuse glioma. Aging (Albany NY). 10:3185–3209. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu YQ, Chai RC, Wang YZ, Wang Z, Liu X,
Wu F and Jiang T: Amino acid metabolism-related gene
expression-based risk signature can better predict overall survival
for glioma. Cancer Sci. 110:321–333. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ma B, Jiang H, Wen D, Hu J, Han L, Liu W,
Xu W, Shi X, Wei W, Liao T, et al: Transcriptome analyses identify
a metabolic gene signature indicative of dedifferentiation of
papillary thyroid cancer. J Clin Endocrinol Metab. 104:3713–3725.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Luo X, Yu H, Song Y and Sun T: Integration
of metabolomic and transcriptomic data reveals metabolic pathway
alteration in breast cancer and impact of related signature on
survival. J Cell Physiol. 234:13021–13031. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu GM, Xie WX, Zhang CY and Xu JW:
Identification of a four-gene metabolic signature predicting
overall survival for hepatocellular carcinoma. J Cell Physiol.
235:1624–1636. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gentric G, Kieffer Y, Mieulet V, Goundiam
O, Bonneau C, Nemati F, Hurbain I, Raposo G, Popova T, Stern MH, et
al: PML-regulated mitochondrial metabolism enhances
chemosensitivity in human ovarian cancers. Cell Metab.
29:156–173.e10. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fabregat A, Jupe S, Matthews L,
Sidiropoulos K, Gillespie M, Garapati P, Haw R, Jassal B, Korninger
F, May B, et al: The reactome pathway knowledgebase. Nucleic Acids
Res. 46:D649–D655. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gautier L, Cope L, Bolstad BM and Irizarry
RA: Affy-analysis of Affymetrix GeneChip data at the probe level.
Bioinformatics. 20:307–315. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Guo JC, Wu Y, Chen Y, Pan F, Wu ZY, Zhang
JS, Wu JY, Xu XE, Zhao JM, Li EM, et al: Protein-coding genes
combined with long noncoding RNA as a novel transcriptome molecular
staging model to predict the survival of patients with esophageal
squamous cell carcinoma. Cancer Commun (Lond). 38:42018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mirzal A: Nonparametric tikhonov
regularized NMF and its application in cancer clustering. IEEE/ACM
Trans Comput Biol Bioinform. 11:1208–1217. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yu N, Gao YL, Liu JX, Shang J, Zhu R and
Dai LY: Co-differential gene selection and clustering based on
graph regularized multi-view NMF in cancer genomic data. Genes
(Basel). 9:E5862018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ye C, Toyoda K and Ohtsuki T: Blind source
separation on non-contact heartbeat detection by non-negative
matrix factorization algorithms. IEEE Trans Biomed Eng. 67:482–494.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li B, Severson E, Pignon JC, Zhao H, Li T,
Novak J, Jiang P, Shen H, Aster JC, Rodig S, et al: Comprehensive
analyses of tumor immunity: Implications for cancer immunotherapy.
Genome Biol. 17:1742016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Love MI, Huber W and Anders S: Moderated
estimation of fold change and dispersion for RNA-seq data with
DESeq2. Genome Biol. 15:5502014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hänzelmann S, Castelo R and Guinney J:
GSVA: Gene set variation analysis for microarray and RNA-seq data.
BMC Bioinformatics. 14:72013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yu G, Wang LG, Han Y and He QY:
clusterProfiler: An R package for comparing biological themes among
gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kostareli E, Hielscher T, Zucknick M,
Baboci L, Wichmann G, Holzinger D, Mücke O, Pawlita M, Del Mistro
A, Boscolo-Rizzo P, et al: Gene promoter methylation signature
predicts survival of head and neck squamous cell carcinoma
patients. Epigenetics. 11:61–73. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhang JX, Song W, Chen ZH, Wei JH, Liao
YJ, Lei J, Hu M, Chen GZ, Liao B, Lu J, et al: Prognostic and
predictive value of a microRNA signature in stage II colon cancer:
A microRNA expression analysis. Lancet Oncol. 14:1295–1306. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Papaemmanuil E, Gerstung M, Malcovati L,
Tauro S, Gundem G, Van Loo P, Yoon CJ, Ellis P, Wedge DC,
Pellagatti A, et al: Clinical and biological implications of driver
mutations in myelodysplastic syndromes. Blood. 122:3616–3627; quiz
3699. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yuan Y, Van Allen EM, Omberg L, Wagle N,
Amin-Mansour A, Sokolov A, Byers LA, Xu Y, Hess KR, Diao L, et al:
Assessing the clinical utility of cancer genomic and proteomic data
across tumor types. Nat Biotechnol. 32:644–652. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Friedman J, Hastie T and Tibshirani R:
Regularization paths for generalized linear models via coordinate
descent. J Stat Softw. 33:1–22. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Subramanian A, Kuehn H, Gould J, Tamayo P
and Mesirov JP: GSEA-P: A desktop application for gene set
enrichment analysis. Bioinformatics. 23:3251–3253. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Liberzon A, Subramanian A, Pinchback R,
Thorvaldsdóttir H, Tamayo P and Mesirov JP: Molecular signatures
database (MSigDB) 3.0. Bioinformatics. 27:1739–1740. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhou J, Yi Y, Wang C, Su C and Luo Y:
Identification of a 3-mRNA signature as a novel potential
prognostic biomarker in patients with ovarian serous
cystadenocarcinoma in G2 and G3. Oncol Lett. 18:3545–3552.
2019.PubMed/NCBI
|
|
50
|
Wang Q, Lu Z, Ma J, Zhang Q, Wang N, Qian
L, Zhang J, Chen C and Lu B: Six-mRNA risk score system and
nomogram constructed for patients with ovarian cancer. Oncol Lett.
18:1235–1245. 2019.PubMed/NCBI
|
|
51
|
An Y, Bi F, You Y, Liu X and Yang Q:
Development of a novel autophagy-related prognostic signature for
serous ovarian cancer. J Cancer. 9:4058–4071. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wang R, Ye XH, Zhao XL, Liu JL and Zhang
CY: Development of a five-gene signature as a novel prognostic
marker in ovarian cancer. Neoplasma. 66:343–349. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Verhaak RG, Tamayo P, Yang JY, Hubbard D,
Zhang H, Creighton CJ, Fereday S, Lawrence M, Carter SL, Mermel CH,
et al: Prognostically relevant gene signatures of high-grade serous
ovarian carcinoma. J Clin Invest. 123:517–525. 2013.PubMed/NCBI
|
|
54
|
Yoshihara K, Tajima A, Komata D, Yamamoto
T, Kodama S, Fujiwara H, Suzuki M, Onishi Y, Hatae M, Sueyoshi K,
et al: Gene expression profiling of advanced-stage serous ovarian
cancers distinguishes novel subclasses and implicates ZEB2 in tumor
progression and prognosis. Cancer Sci. 100:1421–1428. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Anderson KS, Cramer DW, Sibani S,
Wallstrom G, Wong J, Park J, Qiu J, Vitonis A and LaBaer J:
Autoantibody signature for the serologic detection of ovarian
cancer. J Proteome Res. 14:578–586. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Yang X, Zhang L and Xie L: Upregulation of
KIF26B, cell migration and proliferation of human ovarian cancer
cell lines in vitro, and patient outcomes from human bioinformatic
analysis. Med Sci Moni. 24:3863–3872. 2018. View Article : Google Scholar
|
|
57
|
Li S, Xie Y, Zhang W, Gao J, Wang M, Zheng
G, Yin X, Xia H and Tao X: Interferon alpha-inducible protein 27
promotes epithelial-mesenchymal transition and induces ovarian
tumorigenicity and stemness. J Surg Res. 193:255–264. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Joshi A, Dai L, Liu Y, Lee J, Ghahhari NM,
Segala G, Beebe K, Jenkins LM, Lyons GC, Bernasconi L, et al: The
mitochondrial HSP90 paralog TRAP1 forms an OXPHOS-regulated
tetramer and is involved in mitochondrial metabolic homeostasis.
BMC Biol. 18:102020. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Valle-Mendiola A and Soto-Cruz I: Energy
metabolism in cancer: The roles of STAT3 and STAT5 in the
regulation of metabolism-related genes. Cancers (Basel).
12:E1242020. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Meng N, Glorieux C, Zhang Y, Liang L, Zeng
P, Lu W and Huang P: Oncogenic K-ras induces mitochondrial OPA3
expression to promote energy metabolism in pancreatic cancer cells.
Cancers (Basel). 12:E652019. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Ha JH, Radhakrishnan R, Jayaraman M, Yan
M, Ward JD, Fung KM, Moxley K, Sood AK, Isidoro C, Mukherjee P, et
al: LPA induces metabolic reprogramming in ovarian cancer via a
pseudohypoxic response. Cancer Res. 78:1923–1934. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Cateau X, Simon P and Noël JC: Stromal
expression of matrix metalloproteinase 2 in cancer-associated
fibroblasts is strongly related to human epidermal growth factor
receptor 2 status in invasive breast carcinoma. Mol Clin Oncol.
4:375–378. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Thurnher M, Gruenbacher G and Nussbaumer
O: Regulation of mevalonate metabolism in cancer and immune cells.
Biochim Biophys Acta. 1831:1009–1015. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Ghesquière B, Wong BW, Kuchnio A and
Carmeliet P: Metabolism of stromal and immune cells in health and
disease. Nature. 511:167–176. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Becker JC, Andersen MH, Schrama D and Thor
Straten P: Immune-suppressive properties of the tumor
microenvironment. Cancer Immunol Immunother. 62:1137–1148. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Colombo I, Garg S, Danesh A, Bruce J, Shaw
P, Tan Q, Quevedo R, Braunstein M, Oza AM, Pugh T and Lheureux S:
Heterogeneous alteration of the ERBB3-MYC axis associated with MEK
inhibitor resistance in a KRAS-mutated low-grade serous ovarian
cancer patient. Cold Spring Harb Mol Case Stud. 5:a0043412019.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: A phase III randomised, double-blind,
placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Wang Y: Comment on ‘Circular RNAs and
their emerging roles as diagnostic and prognostic biomarkers in
ovarian cancer,’. Cancer Lett. 2020 Jan 2; 473 (2020) 139–147.
Cancer Lett. 475:12020. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Martin de la Fuente L, Westbom-Fremer S,
Arildsen NS, Hartman L, Malander S, Kannisto P, Måsbäck A and
Hedenfalk I: PD-1/PD-L1 expression and tumor-infiltrating
lymphocytes are prognostically favorable in advanced high-grade
serous ovarian carcinoma. Virchows Arch. Jan 24–2020.(Epub ahead of
print). View Article : Google Scholar : PubMed/NCBI
|
